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Abstract 
 
Objective 
The purpose of this study was to establish the relationship of plasma levels of brain natriuretic peptide 
(BNP) to physiological parameters and cardiac morphological characteristics in a population of young 
athletes. Our hypothesis is that physiological and cardiac morphological characteristics do not predict BNP 
levels in adolescent athletes. 
 
Design  
Observational study 
 
Setting  
Outpatient hospital 
 
Patients 
30 healthy male adolescent high school football players (16.0 +/- 1.1 yrs) 
 
Intervention 
Physical exam, electrocardiography, plasma BNP measurement by rapid fluorescent immunoassay, and 
limited echocardiography 
Main Outcome Measure 
Null hypothesis: physiologic parameters and cardiac morphology do not predict plasma BNP levels in 
healthy adolescent football players. Significance level set at p < 0.05. 
 
Results 
Plasma BNP for this population was 11.9 +/- 10.2 pg·ml¯¹. There was no correlation between BNP and 
mean arterial pressure (r = -0.09, p = 0.64), BMI (r = 0.11, p = 0.57), interventricular septal thickness (r = -
0.15, p = 0.44), left ventricular wall thickness (r = 0.00, p = 0.99), relative wall thickness (r = -0.04, p = 
0.84), left ventricular mass (r = 0.05, p = 0.79), or left ventricular mass index (r = 0.11, p = 0.55). 
 
Conclusion 
Plasma BNP levels in healthy adolescent athletes have no correlation to BMI or LV mass, even when 
corrected for body surface area. 
 
Keywords child; electrocardiography (EKG); cardiac physiology; echocardiography 
 
 
Introduction.  
 
Brain, or B-type, natriuretic peptide (BNP) is a 32 amino acid peptide synthesized and secreted from the 
human heart in response to left ventricular wall stress. It has been shown to cause natriuresis, inhibit the 
renin-angiotensin-aldosterone system, reduce plasma volume, and modulate vascular tone 1. Plasma BNP 
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levels have been reliably demonstrated to be elevated in several cardiomyopathic states, including systolic 
and diastolic dysfunction, left ventricular hypertrophy, hypertrophic cardiomyopathy (HCM), and abnormal 
left ventricular filling patterns 1, 2. BNP levels have been found to be transiently elevated in competitive 
athletes engaged in endurance events3. Although plasma levels of BNP have been studied in healthy adult 
athletes and found to correlate to LV mass 4, this is not without contradictory findings 5. It has been 
suggested that BNP may be useful to screen for HCM in young athletes6. 
 
Bedside testing of plasma BNP levels is rapid, inexpensive, and shows linear measurements of BNP 
between 5 and 1300 pg·ml¯¹. Normal values for plasma BNP have been established in healthy controls from 
neonates to adolescents 7; however, there are no data currently available regarding correlation of BNP and 
physiologic characteristics of hearts in young athletes. The purpose of this study is to measure plasma 
levels of brain natriuretic peptide (BNP) and determine its correlation to physiological parameters and 
cardiac morphological characteristics in a population of young athletes.  
 
Methods.  
 
30 males between the ages of 14 and 18 from the local state champion high school football team were 
asked to voluntarily participate upon scheduling a state-required preparticipation physical exam. For 
purposes of detecting a meaningful difference in BNP levels from published reports, a cohort of 30 subjects 
should yield a statistical power >0.8, the number being capped at 30 due to availability of study resources. 
Participants would have been excluded from consideration if they had known cardiac disease or congenital 
malformation, kidney disease, or history of cardiac surgery; none met exclusion criteria. 
 
Data collection occurred during the off-season (summer). Participants refrained from hard physical activity 
for 24 hours prior to the study. Study subjects filled out a standardized questionnaire for preparticipation 
physical exams, had blood pressure, heart rate, height, and weight determination, and underwent physical 
exam.  
 
A single venous sample of blood was collected from each participant. Plasma BNP levels were then  
measured according to the manufacturer’s instructions within two hours on the Triage® BNP testing meter 
(Biosite, Inc., San Diego, CA).  
 
Each study participant had an electrocardiogram (EKG) performed which was interpreted by a board 
certified pediatric cardiologist. Each study participant underwent limited left ventricular echocardiography 
while the pediatric cardiologist was present to oversee the procedure and interpret the results. The pediatric 
cardiologist was blinded to the results of the BNP measurement.  
 
LV mass index was calculated by dividing the LV mass by body surface area (BSA). 
Left ventricular wall thickness = IVSTd + LVPWd 
Relative wall thickness = IVSTd+LVPWd / LVEDD 
 
Descriptive statistics were employed to define the cohort, and EKG findings were described. BNP levels 
were compared with univariate linear regression analysis to BMI, mean arterial pressure, and 
echocardiographic parameters. Significance level defined as p < 0.05. All statistics were completed on 
SPSS v.10.0 (SPSS, Inc., Chicago, IL). 
 
Ethical considerations.  
 
Institutional Review Board approval was obtained from Boise State University prior to study initiation. 
Written informed consent was obtained from all participants and their legal guardians.  
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Results.  
 
Characteristics of study subjects are presented in Table 1. There were no abnormal cardiovascular findings 
on any physical exam. 
 
Electrocardiographic characteristics of study subjects are presented in Table 2. No echocardiographic 
abnormalities were found. 
 
Plasma BNP measurements (mean +/- SD) were 11.9 +/- 10.2 pg·ml¯¹ and ranged from undetectable (<5 
pg·ml¯¹) to 41.7 pg·ml¯¹. 
 
Echocardiographic characteristics of study subjects are presented in Table 3. 
 
There was no significant correlation between BNP values and mean arterial pressure (r = -0.09, p = 0.64), 
BMI (r = 0.11, p = 0.57), interventricular septal thickness (r = -0.15, p = 0.44), LV wall thickness (r = 0.00, 
p = 0.99), relative wall thickness (r = -0.04 p = 0.84), LV mass (r = 0.05, p = 0.79), or LV mass index (r = 
0.11, p = 0.55).  Scatter diagram is shown in Figure 1. 
 
Discussion.  
 
Our results document levels of plasma BNP as well as the electrocardiographic and echocardiographic 
characteristics of a healthy young male group of athletes, and find no significant correlation between the 
plasma BNP levels measured in these athletes and BMI, MAP, or observed cardiac parameters. 
 
Morphologic evaluation of the heart has been reliably conducted since the early 1970’s with 
echocardiography, the noninvasive use of ultrasound-generated images of the heart to quantify cardiac 
dimensions and dynamic function 8. Since that time, ranges of cardiac dimensions have been studied and 
described in virtually all populations, including children9, 10 , athletes 4, 11-17, and patients with HCM 18, 19. 
Echocardiography has also allowed the morphologic characterization of athlete’s heart syndrome, a 
constellation of physiologic adaptations to exercise that maintains or enhances cardiac function in response 
to stress.20 The development of biventricular enlargement in athlete’s heart syndrome presents a challenge 
in differentiating young athletes with HCM from those with cardiac adaptation to exercise.21 Reference 
echocardiographic measurements in children and adolescents have been historically based on normalizing 
values to body surface area9, 10.  Studies describing norms and upper limits of cardiac measurements in 
young athletes are given for comparison in Table 4. Echocardiography in our study population (Table 3) 
did not reveal any pathologic cardiac lesions, and measurements obtained were mostly below the upper 
limits of normal in young athletes.  
 
The EKG findings in our population of athletes were in keeping with prior descriptions of athletic subjects 
20
 and of normal adolescents. All of the features noted by electrocardiography have been found in 
populations of athletes without pathologic cardiac changes, and have been attributed to physiologic 
adaptation to enhance cardiac function, including increased parasympathetic tone and biventricular 
enlargement 20. This underscores an important point about electrocardiography in athletes and adolescents: 
benign aberrances in EKG’s are common, and may demonstrate an electrophysiologic adaptation to 
exercise that has not grossly manifested as a morphologic adaptation. In this regard, these EKG findings 
should be viewed as normal.  
 
The Breathing Not Properly study established BNP levels > 100 pg/ml to be sensitive at differentiating 
CHF from lung disease in the emergency department22; this has been further stratified to differentiate “gray 
zone” BNP levels from 100-500 pg/ml in the REDHOT study23. In practice, utilizing BNP for heart failure 
diagnosis and monitoring must take into consideration factors such as age and gender, but there are 
generally no situations where BNP levels are routinely and persistently elevated >100 pg/ml without 
underlying cardiac pathology24. We were able to identify three studies published specifically to describe 
normal levels of BNP in neonates to adolescents7, 25, 26. Several studies have reported the value of using 
plasma BNP levels in children to assess status of various cardiac disorders, including VSD27, heart  
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transplant28, CHF vs. lung disease29, chemotherapy30, Duchenne’s muscular dystrophy31, Kawasaki32, and 
congenital heart disease33, 34.  These studies have reported BNP levels from 20 – 100 pg/ml as sufficiently 
sensitive and specific to discern a clinical difference.  While the utility of BNP measurement in HCM has  
yet to be fully elucidated35, 36, it has been suggested that increased expression of BNP may be a 
characteristic feature of HCM2. BNP values from our study population of 11.9 +/- 10.2 pg·ml¯¹ are 
comparable to prior studies of BNP levels in normal adolescents 7, 26 (Table 5). To our knowledge, this is 
the first study on BNP levels in a population of adolescent athletes. 
 
It should be acknowledged that this study was limited by a small sample size and the fact that no subjects 
showed abnormal cardiac structural changes. Results should be interpreted in this light and used as a basis 
for further studies on the subject.  
 
Conclusions.  
 
Our findings demonstrate that adolescent athletes have similar levels of BNP when compared to normal 
healthy children, and imply there is no correlation between LV morphology and BNP levels in a young 
healthy athletic population. Future research should evaluate BNP levels in other athletic groups and in 
athletes with echocardiographic changes of increased LV mass, to better define the role of BNP levels in 
detecting cardiac pathology.  
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Table 1 Characteristics of study subjects. Values are mean +/- SD. 
 
Age (yrs) 16.0 +/- 1.1 
BMI 23.8 +/- 3.1 
BSA (m²) 1.9 +/- 0.2 
HR 62.6 +/- 8.7 
Systolic blood pressure 118.9 +/- 12.3 
Diastolic blood pressure 69.6 +/- 7.9 
MAP 86 +/- 7.8 
 
 
 
 
Table 2 Frequency of electrocardiographic findings in study subjects 
 
Sinus arrhythmia 13 
Bradycardia (HR < 60 bpm) 12 
Normal 7 
Left ventricular hypertrophy (R wave in aVL > 11  mm) 2 
Early repolarization (benign ST segment elevation) 2 
Intraventricular conduction delay (QRS > 0.10 s) 2 
Rightward axis (90-120 degrees) 1 
Short PR (PR < 0.12 s) 1 
Fusion complexes with ventricular escape 1 
 
 
Table 3 Echocardiographic measurements.  IVSTd = interventricular septal thickness in diastole; LVPWd 
= LV posterior wall thickness in diastole; LVEDD = left ventricular end diastolic dimension. Values given 
as mean +/- SD. 
N 30 
Median Age (yrs) 16.0 +/- 1.1 
IVSTd (mm) 8.4 +/- 1.6 
LVPWd (mm) 9.2 +/- 1.6 
LVEDD (mm) 51.9 +/- 4.1 
LV wall thickness (mm) 17.6 +/- 2.8 
LV mass (g) 190.2 +/- 38.7 
LV mass index (g/m²) 98.3 +/- 17.6 
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Table 4. Echocardiographic measurements from other studies for comparison, presented as mean +/- SD. 
See Table 3 for abbreviation key. *Normative data presented by body surface area (BSA); these data are 
presented for a BSA of 2.0 m². †A review of 25 prior studies. 
 
Study n Median Age (yrs) 
IVSTd 
(mm) 
LVPWd 
(mm) 
LVEDD 
(mm) LV mass (g) 
LV mass index 
(g•m¯²) 
Kampmann*10 2036  9.3 +/- 1.25 8.1 +/- 1.5 53.4 +/- 4    
Maron†15 381-701 23 10.4 10.7 53.9 265   
Somauroo, et 
al14 171 16.7 
10.3 +/- 
1.4 
10.0 +/- 
1.5 
51.4 +/- 
3.9 229.8 +/- 44   
Sharma, et 
al17 720 15.7 9.4 +/- 1.3 9.3 +/- 1.3 
50.8 +/- 
3.7  113 +/- 33.3 
Date - 
Dynamic4 20 26.8 +/- 8.5    318.3 +/- 48   
Date - Static4 15 24.7 +/- 2.6    496.2 +/- 114.8   
Almeida, et al5 8 29.9 +/- 0.8     180.7 +/- 10.3 
Yamazaki, et 
al16 7 20 +/- 1         152.3 +/- 16.2 
 
 
Table 5. Plasma BNP measurements from previous studies of children and adolescents. BNP values given 
as mean +/- SD. 
 
Study n Age (yrs.) BNP (pg•ml¯¹) +/- SD 
Ationu & Carter25 20 10.0-15.0 31 +/- 4 
Koch & Singer7 31 10-17.6 5.1 +/- 3.5 
Yoshibayashi, et al.26 40 0-16 9.3 +/- 4.8 
Kunii, et al.37 253 0-16 5.3 +/- 3.8 
Ohuchi, et al.38 54 1.0-40 4 +/- 4 
Law, et al.34 17 0.3-18.5 22 +/- 5 
 
 
 
Figure 1 Scatter diagram of physiologic paramaeters  vs. BNP levels 
 
 
 
